New antibody targets lupus in first human trial
NCT ID NCT07491900
Summary
This is an early safety study testing a new antibody drug called HB2198 in adults with moderate to severe lupus. About 30 participants will receive two doses to check how safe it is, find the right dose, and see if it helps reduce lupus activity. The study will follow participants for a year to monitor safety and look for early signs of improvement in lupus symptoms and kidney health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Investigational site
RECRUITINGBrisbane, Australia
Conditions
Explore the condition pages connected to this study.